Editas gene-editing drug slashes multiple cholesterol markers in animal tests
Editas Medicine (NASDAQ:EDIT) presented preclinical data for its lead in vivo gene-editing candidate, EDIT-401, demonstrating that a single dose slashed three key drivers of cardiovascular disease by 90% or more in non-human primates.
The Cambridge, Massachusetts-based biotechnology firm delivered the oral presentation Monday at the 94th European Atherosclerosis Society (EAS) Congress in Athens, Greece.
The findings reinforce the therapeutic potential of Editas’s low-density lipoprotein receptor (LDLR) upregulation approach, which aims to provide a one-time treatment for hyperlipidemia—specifically targeting high-risk patients with inherited genetic disorders like heterozygous familial hypercholesterolemia.
In the non-human primate studies, a single administration of EDIT-401 achieved a mean reduction of 90% or greater in low-density lipoprotein cholesterol (LDL-C).
The therapy also triggered rapid, dose-dependent reductions of approximately 90% in both lipoprotein(a) and apolipoprotein B (ApoB), which serve as key predictive indicators for plaque buildup and atherosclerotic cardiovascular disease.
The synchronized drops across all three atherogenic lipoproteins support a unified clearance mechanism driven by the upregulation of liver LDLR proteins.
Investigators reported that interim data from an ongoing Good Laboratory Practice (GLP) toxicology study showed the treatment was well-tolerated at the therapeutically relevant dose of 1.5 mg/kg, with no adverse clinical observations or treatment-related liver enzyme elevations.
The positive data lands alongside supportive regulatory feedback from the U.S. Food and Drug Administration regarding the company's nonclinical package, manufacturing controls, and initial clinical design framework.
Editas confirmed it is on track to submit a Clinical Trial Notification (CTN) in Australia by mid-2026 to transition the program into human trials.
The company aims to secure early in vivo human proof-of-concept data by the end of 2026, ahead of broader dose-finding clinical results expected in 2027.
